Restarting Research Plans

A provisional plan has been put in to place for restart of clinical research and laboratory (pre-clinical) research activities.

View Research Restart Process >

Coordination of COVID-19 Research

Leadership at the University of Pittsburgh and UPMC has designated the Clinical and Translational Science Institute as the central hub for collecting information and providing resources related to COVID-19 research studies (see full announcement below). This directive applies to any and all human participant research and basic/pre-clinical research.

If your research team at the University of Pittsburgh or UPMC is 1) currently conducting COVID-19 research; 2) planning to implement COVID-19 research; or 3) amending a current research study to include COVID-19 measures, please click on the survey link below to submit a description of your work and identify any resources (e.g., funding, collaborations, lab, regulatory, recruitment) that may be needed. For general questions, please email covid19research@pitt.edu.

Our goal is to remove barriers and expedite your research as we face this unprecedented health threat.

Following your submission, a research facilitator will quickly evaluate and respond to your needs. (Even if you do not require assistance with your study, please submit your information and we will catalog it in our database.)

Select your research type to be directed to a short survey

HUMAN PARTICIPANT RESEARCH BASIC/PRE-CLINICAL RESEARCH

Dear Colleagues,

Research teams at the University of Pittsburgh and UPMC have mobilized to plan and implement clinical trials and clinical research studies related to COVID-19. Given the rapidity of the spread of disease, timely and efficient implementation of studies are critical to their success.

To support and facilitate these studies, we are mobilizing the Clinical and Translational Science Institute (CTSI), to help coordinate resources, expertise, research tools, and lab capabilities.

CTSI will catalogue every Pitt or UPMC COVID-19 related research protocol involving human subjects and/or associated biosamples, electronic health record and other data. This will enable Pitt and UPMC to:

  • Identify collaborative opportunities among study teams
  • Coordinate with HRPO to streamline regulatory submissions
  • Assess researchers’ needs
  • Provide research tools (e.g., electronic consents)
  • Leverage expertise (e.g., study design)
  • Link to institutional resources (e.g., biobanking, Health Record Research Request (R3))
  • Harmonize data elements across studies
  • Help provide integration with national and international research efforts

We are asking all principal investigators planning or conducting COVID-19 related studies to submit a brief description of their proposal at https://www.covid-19research.pitt.edu/.

Finally, funding opportunities are available from multiple sources. You can find details on this link same as noted above.

Please send requests for additional information, or send ideas that are not yet formed into a defined project to covid19research@pitt.edu.

Arthur S. Levine
Senior Vice Chancellor for the Health Sciences

Rob A. Rutenbar
Senior Vice Chancellor for Research

Steven D. Shapiro
Chief Medical and Science Officer

Dear Colleagues,

The COVID-19 pandemic is presenting tremendous challenges to our society. The progress made to date has been largely driven by previously elucidated knowledge about virology, immunology, biochemistry and molecular biology, and other fields. To promote aggressive social distancing and slow the spread of the SARS-CoV-2 infections, the University of Pittsburgh has shut down all but essential on-campus research.

Some basic science research has the potential to aid efforts to fight the COVID-19 pandemic in the short- and medium-term. In order to help coordinate this research and to optimize the potential impact of this research across the University and around the world, we would like all investigators working on such research to provide information about their projects. While research from many fields may be beneficial to these efforts, we are seeking to catalogue only those projects that are (1) directly focused on COVID-19 disease or management or the SARS-CoV-2 virus and (2) have the potential to have impacts of progress in the short- or medium-terms.

Please send requests for additional information or send ideas that are not yet formed into a defined project to covid19research@pitt.edu.

Jeremy M. Berg
Associate Senior Vice Chancellor for Science Strategy and Planning in the Health Sciences

Arthur S. Levine
Senior Vice Chancellor for the Health Sciences

Rob A. Rutenbar
Senior Vice Chancellor for Research

Requests to Participate in COVID-19 Trials

With the recent media coverage of UPMC and the University of Pittsburgh’s research into a vaccine for COVID-19, we have received many requests to participate in COVID related studies. Please send all requests to covid19research@pitt.edu for consideration.

COVID-19 Funding Opportunities

SPONSOR PROGRAM FUNDING DEADLINE

National Institutes of Health (NIH)

NIAID, NIGMS

Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional) Not limited 2/6/2021 (rolling basis)

National Science Foundation (NSF)

Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19) $200,000 Check with program officers

National Institutes of Health (NIH)

NCI, NCCIH, NHGRI, NIAID, NICHD, NIDDK, NIEHS, NIGMS, NIMHD, NIBIB

Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional) Not limited See Emergency Notice of Special Interest by IC

National Institutes of Health (NIH)

NIDA

Notice of Special Interest (NOSI) Regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus $100,000 direct costs/year 3/31/2021 (rolling basis)

Amazon Web Services (AWS)

AWS Diagnostic Development Iniative (DDI) Up to $20M available 6/30/2020

Biomedical Advanced Research and Development Authority (BARDA)

Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) Negotiated after white paper stage 10/31/2020

National Institutes of Health (NIH)

NCATS

Notice of Special Interest (NOSI): Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Heath Need Must reflect your needs 7/9/2021

Pitt Office of Sponsored Programs

The Office of Sponsored Programs provides real-time, updated information on all funding opportunities for research on COVID-19 Various Various

National Institutes of Health (NIH)

NIAID

Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Must reflect your needs 3/25/2021 (rolling basis)

National Institutes of Health (NIH)
NHLBI

Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19) Must reflect your needs 10/6/2020 (rolling basis)

Mozilla Open Source Support Program (MOSS)

COVID-19 Solutions Fund Up to $50,000 each Rolling Basis

National Institute of Biomedical Imaging and Biomedical Engineering

Notice of Special Interest (NOSI): Small Business Research and Development of Biomedical Technologies for Coronavirus Disease 2019 (COVID-19) Must reflect your needs 3/21/2021

National Institute of Biomedical Imaging and Biomedical Engineering

Notice of Special Interest (NOSI): Availability of Emergency Competitive Revision and Administrative Supplements on Biomedical Technologies for Coronavirus Disease 2019 (COVID-19) Must reflect your needs 11/10/2020

National Institute on Alcohol Abuse and Alcoholism

Notice of Special Interest (NOSI): Availability of Administrative Supplements and Urgent Competitive Revisions for Research on Stress Management in Relation to Coronavirus Disease 2019 (COVID-19). Must reflect your needs 10/6/2020

Department of Defense

Air Force Acquisition COVID-19 Task Force (DAF ACT) Commercial Solution Opening (CSO) Not limited 9/30/2020

NASA

Rapid Response and Novel Research in Earth Science. Total funding $600M 3/19/2021

American Lung Association (ALA)

COVID-19 Action Initiative Total funding $25M Rolling Basis

Federal Communications Commission

COVID-19 Telehealth Program Total funding $200M Rolling basis

POCTRN

Rapid Acceleration of Diagnostics (RADx) Total funding up to $500M Rolling basis

Office of Infectious Disease

STOP Spillover Total funding: $50M - $99.99M 8/31/2020
Notice of Special Interest (NOSI): Limited Competition for Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations Must reflect your needs 8/7/2020
Notice of Special Interest (NOSI): Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations Must reflect your needs 8/7/2020
Notice of Special Interest (NOSI): Emergency Competitive Revisions for Social, Ethical, and Behavioral Implications (SEBI) Research on COVID-19 Testing among Underserved and/or Vulnerable Populations Must reflect your needs 8/7/2020
Emergency Awards: RADx-UP Coordination and Data Collection Center (CDCC) (U24 Clinical Trial Optional) Max $700,000 8/7/2020
SPONSOR PROGRAM FUNDING DEADLINE

Clinical & Translational Science Institute

COVID-19 Pilot Grant Program $200,000 (total funding available) 4/3/2020

Centers for Disease Control (CDC)

Applied Research to Address The Coronavirus (COVID-19) Emerging Public Health Emergency $10,000,000 (total funding available) 3/25/2020

Medical CBRN Defense Consortium

Request for Information (RFI) - CoV Pandemic Response Not limited 5/31/2020 (rolling basis)

LifeArc

LifeArc COVID-19 Fund £10M (total funding available) 4/6/2020

American Heart Association (AHA)

AHA Rapid Response Grant COVID-19 and Its Cardiovascular Impact Up to $100,000 4/6/2020

Medical Technology Enterprise Consortium (MTEC)

Development of Treatments for COVID-19 Up to $500,000 4/8/2020

Department of Health and Human Services

Hospital Associations COVID-19 Preparedness and Response Activities $50,000,000 3/30/2020

National Institutes of Health (NIH)

NIEHS

Notice of Special Interest: NIEHS Worker Training Program Coronavirus and Infectious Disease Response Training (Admin Supp Clinical Trial Not Allowed) Not limited 4/24/2020

National Institutes of Health (NIH)

NHGRI

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus Up to $250,000/year in direct costs. Must reflect your needs. 5/16/2020 (rolling basis)

Center for Global Health/CDC/DHHS

Building Capacity for National Public Health Institutes $15,000,000 5/4/2020

National Center for Advancing Translational Sciences/NIH/DHHS

Clinical Trial Planning: Therapeutic/Indication Pairing Strategies (U34) (Clinical Trial Not Allowed) $225,000 6/16/2020

National Center for Advancing Translational Sciences/NIH/DHHS

Limited Competition: Competitive Revision Awards for the Clinical and Translational Science Award (CTSA) Program (U54 Clinical Trial Optional) $750,000 5/4/2020

Center for Medical Innovation Swanson School of Engineering

Early Stage Medical Technology Pilot Funding Program Up to $25,000 4/8/2020

Harrington Discovery Institute

Harrington Scholar Award for Coronavirus Up to $1M 4/30/2020

Fast Grants

Fast Funding for COVID-19 Science Up to $50,000 4/12/2020

National Institute of Biomedical Engineering

Notice of Special Interest (NOSI): Development of Biomedical Technologies for Coronavirus Disease 2019 (COVID-19) Must reflect your needs 6/5/2020

National Institute of General Medical Sciences

Notice of Special Interest (NOSI): Urgent Competitive Revisions to Accelerate Research on the Development of Predictive Models of the Spread of SARS-CoV-2 and Outcomes of Potential Public Health Interventions on COVID-19 Must reflect your needs 5/5/2020

National Cancer Institute

Notice of Special Interest (NOSI): National Cancer Institute Announcement Regarding Availability of Urgent Competitive Revision and Administrative Supplements on Coronavirus Disease 2019 (COVID-19). Up to $100,000/year in direct costs. 6/25/2020

National Institute of Diabetes and Digestive and Kidney Diseases

Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) Related to HIV Comorbidities, Coinfections, and Complications within NIDDK's Mission. Must reflect your needs 6/1/2020

C3.ai Digital Transformation Institute

Immediate First Call for Proposals – AI Techniques to Mitigate Pandemic $5.8M (Total funding available) 5/1/2020

Emergency Medicine Foundation (EMF)

COVID-19 Research Grant Opportunities Up to $100,000 6/5/2020

Patient-Centered Outcomes Research Institute (PCORI)

COVID-19 Targeted PFA Total funding $30M 5/26/2020